Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elinogrel vs Clopidogrel in Non-Urgent PCI
NCT00751231Phase 2Completed
- Sponsor
- Portola Pharmaceuticals
- Start
- Dec 2008
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of elinogrel in coronary artery disease (CAD) (4 arms), sponsored by Portola Pharmaceuticals. Primary endpoint: Clinical efficacy, biological activity, tolerability and safety at 60 days. Started Dec 2008; status: completed.
02
Drugs
elinogrel
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00751231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00751231.